Indirect comparison of Ixekizumab versus Guselkumab up to week 12

被引：0
|
作者：
Gottlieb, A. B. [1 ]
Ramot, Y. [2 ]
Smith, S. D. [3 ]
Saure, D. [4 ]
Schacht, A. [4 ]
Dossenbach, M. [4 ]
Wilhelm, S. [4 ]
Thaci, D. [5 ]
Eppendorfer, S. [6 ]
机构：
[1] Metropolitan Hosp New York, New York Med Coll, New York, NY USA
[2] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Eli Lilly & Co, Indianapolis, IN USA
[5] Univ Hosp Schleswig Holstein, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[6] Lilly Deutschland GmbH, Bad Homburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P108
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [31] Additional efficacy benefit of continuous ixekizumab every-2-week dosing among patients with psoriasis who do not respond by week 12
    Papp, K.
    Gooderham, M.
    Polzer, P.
    Zhang, L.
    Augustin, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E297 - E298
  • [32] Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study
    Bonifati, C.
    Lembo, S.
    Richetta, A. G.
    Romanelli, M.
    Satolli, F.
    Corazza, M.
    Atzori, L.
    Lasagni, C.
    Potenza, C.
    Savoia, P.
    Bardazzi, F.
    Di Lernia, V. G.
    Bianchi, L.
    Fabbrocini, G.
    Giofre, C.
    Zichichi, L.
    Guarneri, C.
    Pallotta, S.
    Fargnoli, M. C.
    Loconsole, F.
    Offidani, A.
    Burlando, M.
    Piaserico, S.
    Peris, K.
    Papini, M.
    Carrera, C. G.
    Costanzo, A.
    Prignano, F.
    Bongiorno, R.
    Dapavo, P.
    Stingeni, L.
    Donini, M.
    Micali, G.
    Rongioletti, F.
    Stinco, G.
    Gramiccia, T.
    Cantini, G.
    Argenziano, G.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024,
  • [33] Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study
    Ruggiero, Angelo
    Fabbrocini, Gabriella
    Cinelli, Eleonora
    Megna, Matteo
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (01)
  • [34] Long term psoriasis control with guselkumab versus secukinumab and ixekizumab among bio- experienced patients: analysis of drug persistence in large claims database
    Zhdanava, Maryia
    Fitzgerald, Timothy
    Pilon, Dominic
    Teneralli, Rachel
    Shah, Aditi
    Holiday, Christopher
    Lefebvre, Patrick
    Feldman, Steven
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB188 - AB188
  • [35] COMPARISON OF THE EFFECTS OF AN EIGHT-WEEK PUSH-UP PROGRAM USING STABLE VERSUS UNSTABLE SURFACES
    Chulvi-Medrano, Ivan
    Martinez-Ballester, Esteban
    Masia-Tortosa, Laura
    [J]. INTERNATIONAL JOURNAL OF SPORTS PHYSICAL THERAPY, 2012, 7 (06): : 586 - 594
  • [36] COVID-19 and hospitalizations for SARI in Brazil: a comparison up to the 12th epidemiological week of 2020
    Bastos, Leonardo Soares
    Niquini, Roberta Pereira
    Lana, Raquel Martins
    Villela, Daniel A. M.
    Cruz, Oswaldo G.
    Coelho, Flavio C.
    Codeco, Claudia T.
    Gomes, Marcelo F. C.
    [J]. CADERNOS DE SAUDE PUBLICA, 2020, 36 (04):
  • [37] Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study
    Georgakopoulos, J. R.
    Phung, M.
    Ighani, A.
    Lam, K.
    Yeung, J.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (01) : E7 - E8
  • [38] Ixekizumab reduces IL-17 and IL-23 pathway genes more rapidly than guselkumab: 4-week results from IXORA-R
    Garcet, Sandra
    Tsoi, Lam C.
    Blauvelt, Andrew
    Papp, Kim A.
    Krishnan, Venkatesh
    Konicek, Bruce
    Dow, Ernst R.
    Gemperline, David
    Elmaraghy, Hany
    Krueger, James
    Gudjonsson, Johann E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB59 - AB59
  • [39] A Comparison of Indirect Versus Experimental Strategies for the Assessment of Pica
    Wasano, Lauren C.
    Borrero, John C.
    Kohn, Carolynn S.
    [J]. JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2009, 39 (11) : 1582 - 1586
  • [40] COMPARATIVE EFFICACY OF GUSELKUMAB AND TILDRAKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Van, Sanden S.
    Diels, J.
    Schubert, A.
    Barthelmes, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S410 - S410
12345